

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Jacques F. BANCHEREAU et al.

U.S. Application No.: 10/042,644

Group Art Unit: 1646

Filing or 371(c) Date: January 8, 2002

Examiner: Gyan Chandra

Title: Methods for Treating Autoimmune Diseases
in a Subject and In Vitro Diagnostic Assays

Confirmation No.: 7691

TWELFTH INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, Applicants hereby submit the following information in conformance with 37 C.F.R. §§ 1.97 and 1.98. A copy of each of the documents cited and required by 37 C.F.R. § 1.98 is enclosed.

To assist the Examiner, the documents are listed on the attached form PTO/SB/08. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.

The cited documents are being submitted within three (3) months of the filing or entry of the national stage of this application or before the first Office Action on the merits, whichever is later. Since these documents are being filed within the time period set forth in 37 C.F.R. § 1.97(b), no fee or statement is required.


This Information Disclosure Statement is being submitted after the period specified in 37 C.F.R. § 1.97(b). Therefore, please charge the fee of \$180.00 as required by 37 C.F.R. § 1.97(c). Consideration of the information provided herein is respectfully requested.

The Director is hereby authorized to charge any appropriate fees that may be required by this paper, and to credit any overpayment, to Deposit Account No. 23-1925.

Respectfully submitted,

BRINKS HOFER GILSON & LIONE

Date: May 6, 2009

By: 
Thomas E. Holsten
Registration No. 46,098

2801 Slater Road, Suite 120
Morrisville, NC 27560
919.481.1111
682096v1